Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended December 31, 2007
Business Overview: BD is a medical technology company operating through three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products globally.
Key Financial Metrics
| Metric | Q1 2008 (Dec 31, 2007) | Q1 2007 (Dec 31, 2006) |
|---|---|---|
| Revenues | $1,705.8 million | $1,501.5 million |
| Operating Income | $362.7 million | $213.8 million |
| Net Income | $271.5 million | $142.9 million |
| Diluted EPS (Continuing Ops) | $1.07 | $0.51 |
| Gross Profit Margin | 51.4% | 52.8% |
| Operating Cash Flow | $473.1 million | $276.1 million |
| Total Debt | $1.166 billion | N/A (Balance Sheet data only) |
| Cash and Equivalents | $750.8 million | $511.5 million (Sep 30, 2007) |
Note: Total debt calculated as Short-term debt ($208.2M) + Long-term debt ($957.6M) as of Dec 31, 2007.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 14% year-over-year, driven by a 9% volume increase and 6% favorable foreign currency translation. Price decreases were less than 1%.
- Profitability Surge: Net income increased significantly ($128.7 million) primarily due to the absence of a $114.7 million non-recurring charge for acquired in-process research and development (TriPath acquisition) recorded in the prior year.
- Segment Performance:
- Medical: Revenues up 10%; Operating income up 7%.
- Diagnostics: Revenues up 18%; Operating income improved from a loss of $0.3 million to $126.9 million (excluding the prior year's acquisition charge).
- Biosciences: Revenues up 18%; Operating income up 40%.
- Margin Pressure: Gross profit margin declined 140 basis points to 51.4%, impacted by higher resin and steel costs, manufacturing start-up costs, and unfavorable currency translation.
- Cash Flow: Operating cash flow increased 71% to $473.1 million, aided by lower pension contributions compared to the prior year ($23 million vs. $75 million).
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2008 Guidance: Management expects gross profit margins to decrease by approximately 20 basis points in 2008 due to raw material costs. Selling and administrative expenses are expected to decrease by 70 basis points as a percentage of revenue. R&D expenses are projected to increase by 11%.
- Tax Rate: The effective tax rate for 2008 is expected to be slightly above 27%.
- Capital Spending: Expected to be approximately $650 million for 2008.
- Share Repurchases: The company repurchased $123 million of common stock in the quarter. Authorization remains for an additional 9.6 million shares.
Risks and Contingencies
- Raw Material Costs: Increased costs for oil-based resins and steel due to rising world oil prices. Management notes that further significant increases could impact future results.
- Legal Proceedings:
- Antitrust: Multiple class-action suits (direct and indirect purchasers) alleging violations of federal antitrust laws regarding pricing. Consolidated in Multi-District Litigation (MDL).
- Patent Litigation: Suit filed by Retractable Technologies, Inc. alleging patent infringement regarding BD Integra syringes and false advertising.
- Product Liability: Pending suits regarding needlestick injuries and natural rubber latex gloves (ceased manufacturing in 1995).
- Regulatory Investigations: Ongoing investigations by the Attorneys General of Connecticut and Illinois regarding the company's participation in the Healthcare Research & Development Institute (HRDI). French Judicial Police investigation regarding the UN Oil-for-Food Programme.
- Foreign Currency: Significant exposure to fluctuations in exchange rates, though partially hedged.
Investor Verification Checklist
- Margin Sustainability: Verify if productivity improvements can continue to offset rising resin and steel costs as projected for 2008.
- Legal Exposure: Monitor the status of the consolidated antitrust MDL and the Retractable Technologies patent litigation for potential material charges.
- Acquisition Integration: Assess the ongoing contribution of the TriPath acquisition to the Diagnostics segment revenue and operating income.
- Debt Covenants: Confirm continued compliance with the interest expense coverage ratio covenant (currently 17-to-1 to 26-to-1, required 5-to-1).
- Regulatory Outcomes: Track the resolution of the HRDI investigations and the French judicial inquiry regarding the UN Oil-for-Food Programme.